0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pharmacom Biovet
Its shares trade under the ticker PHMB. It has been listed since 6 June 2001.
PharmaCom BioVet, Inc. engages in the provision of locating, identifying, and introducing cancer compounds and treatment procedures into the veterinary market. The company is headquartered in Raleigh, North Carolina. The company went IPO on 2001-06-06. The firm is introducing canine bone marrow transplantation. ABV Gold Inc. was a gold and precious metals mining company founded as an exploration company to locate, explore and mine deposits. The firm holds claims in three different properties: The Toiyabe Uranium, the Parin Mining, and the Dun Glen properties.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 6 Jun 2001
- Employees
- 2
Leadership
Pay as last reported
- Daniel RyanPresident
- Peter PrestonChief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director, since 1999
- Russell HeatonPresident of Plan B Productions of Utah, Inc, Director, since 2002
- Enzo VetteseDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Pharmacom Biovet Inc has a strong reputation in the pharmaceutical industry, known for its high-quality products and effective medications.
- The company has a robust research and development department, ensuring constant innovation and the introduction of new drugs to the market.
- Pharmacom Biovet Inc has a wide distribution network, allowing its products to reach global markets and maximize sales potential.
Weaknesses
- The company heavily relies on a few key products, which may expose it to vulnerability if there are any adverse events or patent expirations.
- Lack of diversification in the product portfolio makes Pharmacom Biovet Inc susceptible to market fluctuations and consumer preferences.
- There is a potential for manufacturing delays or quality control issues, which could damage the company's reputation and customer trust.
Opportunities
- Expansion into emerging markets, especially in developing countries, presents an opportunity for increasing sales and market presence.
- Pharmacom Biovet Inc can leverage advancements in technology and invest in digital solutions for improved customer engagement and streamlined operations.
- Collaboration with academic institutions and research organizations can lead to the development of breakthrough drugs and further enhance the company's reputation.
Threats
- Intense competition from other pharmaceutical companies may limit market share and put pressure on pricing.
- Changes in government regulations and policies regarding drug approval and pricing can significantly impact the company's operations and profitability.
- Potential disruptions in the supply chain or raw material shortages can disrupt production and hinder the timely delivery of products to customers.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.